GILEAD SCIENCES INC 3.5 percent 01Feb2025 is a Senior Unsecured Note issued by the corporate entity on the 12th of November 2014. GILEAD is trading at 99.65 as of the 26th of November 2024, a 0.10% up since the beginning of the trading day. The bond's open price was 99.55. GILEAD has about a 41 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Ratings for GILEAD SCIENCES INC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of December 2022 and ending today, the 26th of November 2024. Click here to learn more.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gileads primary areas of focus include human immunodeficiency virus AIDS, liver diseases, such as hepatitis B and C and cardiovascularmetabolic and respiratory conditions. More on GILEAD SCIENCES INC
Our tools can tell you how much better you can do entering a position in GILEAD without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Pair Correlation Now
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
GILEAD financial ratios help investors to determine whether GILEAD Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GILEAD with respect to the benefits of owning GILEAD security.